Protalix BioTherapeutics, Inc. (PLX) Q1 2026 Earnings Call Transcript
Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results
Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026
Protalix Revenue Miss Overshadowed By Milestone-Backed 2026 Guidance
Americans are richer in shares, Europeans in bricks – and that matters now
Tesla targets December 2026 for next-generation AI6 chip tape-out
Protalix BioTherapeutics, Inc. (PLX) Q4 2025 Earnings Call Transcript
Protalix BioTherapeutics advances Fabry disease and gout programs during 2025
Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results
Protalix BioTherapeutics advances Fabry disease and gout programs during 2025
Pennon shares rise despite profit warning as storm costs and sewage penalties bite
Physiomics shares fall 27% after discounted share placing
Protalix BioTherapeutics and partner secure EU approval for new Fabry disease dosing regimen
Protalix BioTherapeutics and partner secure EU approval for new Fabry disease dosing regimen
Ticketmaster owner Live Nation reaches antitrust settlement with US Justice Department
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa)
Reviewing Protalix BioTherapeutics (NYSE:PLX) & JATT Acquisition (NYSE:JATT)
Polaryx to Present Late-Breaker Data Related to SOTERIA at the 22nd Annual WORLDSymposium™ as Company Prepares for SOTERIA Trial Launch
A March Decision That Could Change Protalix BioTherapeutics Outlook
Protalix wins EU panel backing for expanded dosing of Fabry disease drug
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EU
Nasdaq leads losses as investors juggle earnings, Fed Chair nomination
Protalix wins EU panel backing for expanded dosing of Fabry disease drug
Protalix BioTherapeutics CEO outlines 2026 priorities, highlights progress across clinical pipeline
Protalix BioTherapeutics Letter to Stockholders
Micron shares jump after strong Q1 earnings, robust outlook
Protalix BioTherapeutics partners with Secarna Pharmaceuticals on rare kidney disease drug development
Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement
Oracle shares slide as $10B Michigan data center faces funding uncertainty
Protalix BioTherapeutics, Inc. (PLX) Q3 2025 Earnings Call Transcript
Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results
PLX Investors Have Opportunity to Join Protalix BioTherapeutics, Inc. Fraud Investigation with the Schall Law Firm
Protalix and Chiesi seek EMA re-examination of Elfabrio dosing opinion
Chiesi Global Rare Diseases and Protalix BioTherapeutics Seek Re-examination from the EMA for the Negative Opinion for Elfabrio (pegunigalsidase alfa) Alternative Dosing Regimen of Every Four Weeks in the EU
PLX Investors Have Opportunity to Join Protalix BioTherapeutics, Inc. Fraud Investigation with the Schall Law Firm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX
Protalix BioTherapeutics (NYSE:PLX) vs. Invizyne Technologies (NASDAQ:IZTC) Critical Survey
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX
Why Is Protalix BioTherapeutics Stock Falling On Friday?
Protalix, Chiesi reaffirm commitment to Fabry disease patients after EMA panel setback
Chiesi Global Rare Diseases and Protalix Biotherapeutics Acknowledge CHMP Negative Opinion on Every Four Week Dosing Regimen of Elfabrio® (pegunigalsidase alfa) in the EU
Protalix BioTherapeutics to Present at Investor Summit Virtual
Protalix: Speculative Buy On Promising Plant-Cell Platform And Elfabrio Ramp
Protalix BioTherapeutics, Inc. (PLX) Q2 2025 Earnings Call Transcript
Protalix BioTherapeutics lifts revenue on strong Elfabrio demand
Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results
Protalix BioTherapeutics to Announce Second Quarter 2025 Financial and Business Results on August 14, 2025
Protalix BioTherapeutics welcomes new finance chief
Protalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial Officer